These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 16400625)

  • 21. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.
    Iqbal J; Neppalli VT; Wright G; Dave BJ; Horsman DE; Rosenwald A; Lynch J; Hans CP; Weisenburger DD; Greiner TC; Gascoyne RD; Campo E; Ott G; Müller-Hermelink HK; Delabie J; Jaffe ES; Grogan TM; Connors JM; Vose JM; Armitage JO; Staudt LM; Chan WC
    J Clin Oncol; 2006 Feb; 24(6):961-8. PubMed ID: 16418494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
    Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
    J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.
    Zinzani PL; Dirnhofer S; Sabattini E; Alinari L; Piccaluga PP; Stefoni V; Tani M; Musuraca G; Marchi E; Falini B; Baccarani M; Pileri SA
    Haematologica; 2005 Mar; 90(3):341-7. PubMed ID: 15749666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bcl-2 and BLIMP-1 expression predict worse prognosis in gastric diffuse large B cell lymphoma (DLCBL) while other markers for nodal DLBCL are not useful.
    Martin-Arruti M; Vaquero M; Díaz de Otazu R; Zabalza I; Ballesteros J; Roncador G; García-Orad A
    Histopathology; 2012 Apr; 60(5):785-92. PubMed ID: 22321048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
    Obermann EC; Csato M; Dirnhofer S; Tzankov A
    J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary lymphoma of bone: extranodal lymphoma with favourable survival independent of germinal centre, post-germinal centre or indeterminate phenotype.
    Heyning FH; Hogendoorn PC; Kramer MH; Holland CT; Dreef E; Jansen PM
    J Clin Pathol; 2009 Sep; 62(9):820-4. PubMed ID: 19734480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor.
    Oh YH; Park CK
    J Korean Med Sci; 2006 Jun; 21(3):397-405. PubMed ID: 16778379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary diffuse large B-cell lymphomas of the bone: prognostic relevance of protein expression and clinical factors.
    Adams H; Tzankov A; d'Hondt S; Jundt G; Dirnhofer S; Went P
    Hum Pathol; 2008 Sep; 39(9):1323-30. PubMed ID: 18614198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2.
    Mainou-Fowler T; Overman LM; Dignum H; Wood K; Crosier S; Angus B; Proctor SJ; Anderson JJ
    Int J Oncol; 2008 Jan; 32(1):59-68. PubMed ID: 18097543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Hasselblom S; Hansson U; Olsson M; Torén L; Bergström A; Nilsson-Ehle H; Andersson PO
    Br J Haematol; 2010 May; 149(4):560-8. PubMed ID: 20201946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.
    Linderoth J; Jerkeman M; Cavallin-Ståhl E; Kvaløy S; Torlakovic E;
    Clin Cancer Res; 2003 Feb; 9(2):722-8. PubMed ID: 12576441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gastric and intestinal diffuse large B-cell lymphomas are clinically and immunophenotypically different. An immunohistochemical and clinical study.
    Connor J; Ashton-Key M
    Histopathology; 2007 Nov; 51(5):697-703. PubMed ID: 17927592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bcl-2, Bcl-X, Bax, and Bak expression in short- and long-lived patients with diffuse large B-cell lymphomas.
    Bairey O; Zimra Y; Shaklai M; Okon E; Rabizadeh E
    Clin Cancer Res; 1999 Oct; 5(10):2860-6. PubMed ID: 10537354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma.
    Frost M; Newell J; Lones MA; Tripp SR; Cairo MS; Perkins SL
    Am J Clin Pathol; 2004 Mar; 121(3):384-92. PubMed ID: 15023043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of transmembrane adaptor protein PAG/Cbp in diffuse large B-cell lymphoma: immunohistochemical study of 73 cases.
    Svec A
    Pathol Res Pract; 2007; 203(4):193-8. PubMed ID: 17382485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation.
    Costa LJ; Feldman AL; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Ansell SM
    Br J Haematol; 2008 Jul; 142(3):404-12. PubMed ID: 18492096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma.
    Dierlamm J; Murga Penas EM; Bentink S; Wessendorf S; Berger H; Hummel M; Klapper W; Lenze D; Rosenwald A; Haralambieva E; Ott G; Cogliatti SB; Möller P; Schwaenen C; Stein H; Löffler M; Spang R; Trümper L; Siebert R;
    Haematologica; 2008 May; 93(5):688-96. PubMed ID: 18367485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas.
    Muris JJ; Ylstra B; Cillessen SA; Ossenkoppele GJ; Kluin-Nelemans JC; Eijk PP; Nota B; Tijssen M; de Boer WP; van de Wiel M; van den Ijssel PR; Jansen P; de Bruin PC; van Krieken JH; Meijer GA; Meijer CJ; Oudejans JJ
    Br J Haematol; 2007 Jan; 136(1):38-47. PubMed ID: 17062006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.